Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine in Indian Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

NCT02658734 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02658734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02658734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine in Indian Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
November 1, 2016
Completion date
December 14, 2019
Enrollment
70 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

her2 positive breast cancer, metastatic breast cancer, locally advanced breast cancer